This study aimed to determine if intravenous iron (ferric carboxymaltose) would improve symptoms in patients with heart failure, reduced left ventricular function, and iron deficiency anemia. Patients with chronic heart failure classified as NYHA class II or III, a left ventricular ejection fraction of 40% or less (II) or 45% or less (III), and microcytic hypochromic anemia were randomly assigned to receive either 200 mg of intravenous iron or a saline placebo. The primary endpoints were self-reported health status and NYHA functional class at 24 weeks, with secondary endpoints including 6-minute walk distance and quality of life.
1 of 5
Downloaded 16 times
More Related Content
Ferric carboxymaltose in patients with heart failure and
2. Iron deficiency may impair aerobic performance.
This study aimed to determine whether treatment
with intravenous iron (ferric carboxymaltose) would
improve symptoms in patients who had heart
failure, reduced left ventricular ejection fraction, and
microcytic hypochromic anemia.
3. chronic heart failure of New York Heart Association
(NYHA) functional class II or III,
a left ventricular ejection fraction of 40% or less
(for patients with NYHA class II) or
45% cor less (for NYHA class III),
Microcytic hypochromic anemia with hb >10
4. Patients were randomly assigned, in a 2:1 ratio, to
receive 200 mg of intravenous iron (ferric
carboxymaltose) or saline (placebo).
The primary end points were the self-reported
Patient Global Assessment and NYHA functional
class, both at week 24. Secondary end points
included the distance walked in 6 minutes and the
health-related quality of life.
